Association of serum coiled-coil domain containing protein 11 levels with coronary artery disease

This study aimed to assess the association between circulating levels of coiled coil domain containing protein 11 (CCDC11) and coronary artery disease (CAD).

A total of 266 patients diagnosed with CAD and 95 controls were enrolled in our center from January 2024 to December 2024. The CAD cohort was further stratified into three subgroups based on the number of affected coronary vessels: the single-vessel group (n = 88), the double-vessel group (n = 74) and the triple-vessel group (n = 104). Serum concentrations of CCDC11 were quantified using an ELISA kit. Spearman correlation analysis was employed to evaluate the relationships between CCDC11 levels and other clinical parameters. Binary logistic regression analysis was conducted to determine the independent association of CCDC11 with CAD. The discriminative ability of CCDC11 for CAD was assessed using receiver operating characteristic (ROC) curve analysis.

Median serum CCDC11 amounts were significantly elevated in the CAD group compared to controls (20.4 vs. 13.8 ng/mL, P < 0.001). Furthermore, serum CCDC11 levels demonstrated a positive trend correlating with the number of lesioned coronary vessels (P for trend < 0.001). Logistic regression analysis revealed that CCDC11 was independently correlated with CAD. In ROC analysis, the area under the ROC curve (AUC) for CCDC11 in discriminating CAD was moderate but significantly higher than that for CRP (0.71 vs. 0.56, P < 0.01). Utilizing the maximum Youden index, an optimal CCDC11 cutoff value of 19.37 ng/mL was identified, yielding a sensitivity of 53.4% and specificity of 91.6% for CAD discrimination.

Elevated serum levels of CCDC11 were positively associated with both the presence and severity of CAD, suggesting that CCDC11 may serve as a novel and clinically valuable biomarker for CAD.